TY - JOUR
T1 - Impact of Stress Ulcer Prophylaxis Discontinuation Guidance in Mechanically Ventilated, Critically Ill Patients
T2 - A Pre-Post Cohort Study
AU - Jones, Christopher A.
AU - Betthauser, Kevin D.
AU - Lizza, Bryan D.
AU - Juang, Paul A.
AU - Micek, Scott T.
AU - Kollef, Marin H.
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: No funding was utilized in the completion of this study and/or preparation of the manuscript. Dr. Kollef’s research efforts are supported by the Barnes-Jewish Hospital Foundation.
Publisher Copyright:
© The Author(s) 2021.
PY - 2022/8
Y1 - 2022/8
N2 - Purpose: Recent data highlight unclear efficacy and potential negative sequelae of stress ulcer prophylaxis (SUP) in the intensive care unit (ICU). Minimizing SUP exposure has pertinent clinical and other implications. This study assessed medication use and clinical outcomes before and after implementation of a practice guideline promoting early discontinuation of SUP in mechanically ventilated ICU patients. Methods: Retrospective, single-center, pre-post cohort study within a medical ICU at a large, academic medical center. Adult patients requiring mechanical ventilation and receiving SUP via a histamine-2 receptor antagonist (H2RA) or proton pump inhibitor (PPI) were eligible for inclusion. The clinical practice guideline was implemented on January 1, 2020. The impact of implementation was assessed via percent of patient-days with inappropriate SUP. Incidence of clinically important GI bleed was the primary safety outcome. Results: A total of 137 pre-guideline and 112 post-guideline patients were included. Comorbidity burden was similar between groups. A higher prevalence of baseline vasopressor receipt (39% vs 67%, P <.01) and acute kidney injury (56% vs 69%, P =.04) was observed in post-guideline patients. Post-guideline patients experienced a significantly lower percentage of patient-days of inappropriate SUP (25% vs 50%, P <.01) as well as higher rates of SUP discontinuation before extubation (71% vs 12%, P <.01) and during ICU stay (93% vs 50%, P <.01). Post-guideline patients observed a significantly lower incidence of SUP at hospital discharge (4% vs 35%, P <.01). No differences in bleeding outcomes were observed, though post-guideline patients experienced longer durations of mechanical ventilation, ICU stay, and hospital stay. Conclusions: Implementation of an early SUP discontinuation guideline was associated with significant improvements in SUP prescribing practices. Baseline differences between groups likely explain observed differences in clinical outcomes.
AB - Purpose: Recent data highlight unclear efficacy and potential negative sequelae of stress ulcer prophylaxis (SUP) in the intensive care unit (ICU). Minimizing SUP exposure has pertinent clinical and other implications. This study assessed medication use and clinical outcomes before and after implementation of a practice guideline promoting early discontinuation of SUP in mechanically ventilated ICU patients. Methods: Retrospective, single-center, pre-post cohort study within a medical ICU at a large, academic medical center. Adult patients requiring mechanical ventilation and receiving SUP via a histamine-2 receptor antagonist (H2RA) or proton pump inhibitor (PPI) were eligible for inclusion. The clinical practice guideline was implemented on January 1, 2020. The impact of implementation was assessed via percent of patient-days with inappropriate SUP. Incidence of clinically important GI bleed was the primary safety outcome. Results: A total of 137 pre-guideline and 112 post-guideline patients were included. Comorbidity burden was similar between groups. A higher prevalence of baseline vasopressor receipt (39% vs 67%, P <.01) and acute kidney injury (56% vs 69%, P =.04) was observed in post-guideline patients. Post-guideline patients experienced a significantly lower percentage of patient-days of inappropriate SUP (25% vs 50%, P <.01) as well as higher rates of SUP discontinuation before extubation (71% vs 12%, P <.01) and during ICU stay (93% vs 50%, P <.01). Post-guideline patients observed a significantly lower incidence of SUP at hospital discharge (4% vs 35%, P <.01). No differences in bleeding outcomes were observed, though post-guideline patients experienced longer durations of mechanical ventilation, ICU stay, and hospital stay. Conclusions: Implementation of an early SUP discontinuation guideline was associated with significant improvements in SUP prescribing practices. Baseline differences between groups likely explain observed differences in clinical outcomes.
KW - critical care
KW - gastrointestinal bleed
KW - histamine-2 receptor antagonist
KW - proton pump inhibitor
KW - stress ulcer prophylaxis
UR - http://www.scopus.com/inward/record.url?scp=85120821793&partnerID=8YFLogxK
U2 - 10.1177/00185787211061371
DO - 10.1177/00185787211061371
M3 - Article
C2 - 35898251
AN - SCOPUS:85120821793
SN - 0018-5787
VL - 57
SP - 510
EP - 517
JO - Hospital Pharmacy
JF - Hospital Pharmacy
IS - 4
ER -